Clinical Trial Update: A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating JNJ-42160443 for diabetic painful neuropathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• JNJ-42160443

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Diabetic Neuropathy | Phase 2 | Status: TERMINATED